Decoy Therapeutics (NASDAQ:DCOY) Short Interest Down 84.7% in July

Decoy Therapeutics (NASDAQ:DCOY) was the recipient of a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 23,986 shares, a drop of 84.7% from the June 30th total of 156,313 shares. Currently, 4.6% of the shares of the company are short sold. Based on an average daily trading volume, of 44,863 shares, the short-interest ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, June 12th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $30.00.

Decoy Therapeutics Stock Performance

Shares of DCOY traded up $0.10 during mid-day trading on Friday, hitting $5.04. 9,632 shares of the company’s stock were exchanged, compared to its average volume of 683,977. Decoy Therapeutics has a 52 week low of $4.32 and a 52 week high of $415.80. The stock has a 50-day moving average of $6.44. The stock has a market capitalization of $2.68 million, a price-to-earnings ratio of -0.05 and a beta of 0.59.

Decoy Therapeutics (NASDAQ:DCOY) last issued its quarterly earnings results on Friday, May 8th. The company reported ($4.18) earnings per share (EPS) for the quarter. Sell-side analysts forecast that Decoy Therapeutics will post -12.97 earnings per share for the current year.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.